Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for Reversal of Neuromuscular Blockade in Pediatric Participants
NCT03351608Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2018
- Primary completion
- Jan 2020
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 8
01
Overview
A Phase 4 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Feb 2018; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03351608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351608.